Mainstream M&A has for decades been the stronghold of the City elite… and the ground US law firms struggled to seize. As some of Wall Street’s elite ramp up City investment, is plc deal work about to fall to US invaders?
With seven days left on the clock to force through a bid for the UK’s largest pharmaceutical company AstraZeneca, many in the City were surprised when Pfizer put forward a final £69bn offer on a spring Sunday evening when most shareholders were out enjoying their weekends.
Subscriber Access
You must be logged in to view full premium content.
